UnicoCell Biomed Co., Ltd. (TPE:6794)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
87.00
+0.10 (0.12%)
Feb 11, 2026, 1:30 PM CST
Market Cap5.27B +29.1%
Revenue (ttm)34.58M +18.9%
Net Income-107.04M
EPS-1.79
Shares Out60.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume23,552
Average Volume53,257
Open88.20
Previous Close86.90
Day's Range85.10 - 88.20
52-Week Range60.80 - 96.00
Beta-0.32
RSI49.00
Earnings DateFeb 25, 2026

About UnicoCell Biomed

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; CDMO; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing services, which include sterility, endotoxin, mycoplasma, and cel... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 27
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6794
Full Company Profile

Financial Performance

In 2024, UnicoCell Biomed's revenue was 31.88 million, an increase of 29.66% compared to the previous year's 24.59 million. Losses were -93.07 million, 10.7% more than in 2023.

Financial Statements